Novavax’s Covid-19 vaccine demonstrates 100% protection against moderate and severe disease

Results from the biotech’s PREVENT-19 trial show NVX-CoV2373 vaccine candidate offers 90.4% overall efficacy.



Novavax reported that its recombinant protein-based COVID-19 vaccine candidate, NVX-CoV2373 has met the primary endpoint in its PREVENT-19 Phase 3 trial, demonstrating 100% protection against moderate and severe disease and 90.4% overall efficacy. The trial enrolled 29 960 participants and was conducted across 119 sites in the United States (U.S). and Mexico. The results also found that the vaccine was similarly effective against newer coronavirus strains, especially the Alpha variant (B.1.1.7) which was first detected in the United Kingdom, now dominant in the U.S. This vaccine candidate is engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease and is administered in two doses, three weeks apart from each other.


Stanley C Erck, the company’s President and CEO, was pleased to announce that Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. The results suggest the vaccine is on track to become the fourth authorized for use in the U.S. However, Novavax plans to file for regulatory approvals in the next quarter upon completion of the final phases of process qualification and assay validation needed to meet manufacturing requirements. Regulatory authorization would infuse a new supply of doses aiding the company reach its target of manufacturing 100 million doses per month by the end of the third quarter and 150 million doses by the end of 2021.